findmyKOL
Clinical trialNCT05102617CompletedInterventional

Post Market Usability Evaluation Of The PicoSure Pro Device

SponsorCynosure, Inc.Enrollment23Acne ScarsBenign Dermal Pigmented LesionsBenign Epidermal Pigmented LesionsTattoo RemovalWrinkle
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The intended use of the PicoSure and PicoSure Pro devices used in this study is to treat additional patients with the new PicoSure Pro device and collect additional data on the devices.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Center for Dermatology and Laser Surgery

    Sacramento, California, United States

  • Cynosure, Inc.

    Westford, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Topical Cosmeceuticals
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Oct 2021
Primary completion
15 Mar 2023
Completion
15 Mar 2023
Last update posted
9 Jan 2024
Registered enrollment
23
Registry id
NCT05102617
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.